worldpharmaceuticals.net
J&J secures FDA approval for Tremfya to treat Crohn's disease
An FDA approval means guselkumab (Tremfya) is now an authorized treatment option for adults with active Crohn’s disease. The drug offers both subcutaneous and IV induction choices and may be relevant for people who did not respond to other therapies.
Adults with Crohn’s disease, especially those considering or on biologic therapies; gastroenterologists and IBD clinicians; researchers following IL-23 treatments.
What To Know
What to know The FDA has approved Tremfya (guselkumab) for adults with active Crohn’s disease. The article reports that Tremfya is an IL-23–targeting monoclonal antibody with both subcutaneous and intravenous induction options, and lists the induction and maintenance dosing regimens described by the manufacturer.
The approval is supported by multiple Phase 3 trials (named GRAVITI and GALAXI in the article) including more than 1,300 patients and pooled analyses reportedly comparing Tremfya with ustekinumab (Stelara). The article also notes Tremfya was previously approved for ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
If you currently take biologic therapy, this approval represents a new, FDA-authorized IL-23 option for Crohn’s disease with a fully subcutaneous induction regimen available. Discussing suitability, switches, or dosing with your gastroenterology team is appropriate before making any changes.
The original article is an industry news piece summarizing the regulatory announcement and company comments; it does not provide full trial data or independent expert analysis.
This is a news summary of the FDA approval and company statements; the article cites Phase 3 trials but does not include full efficacy or safety data. Patients should consult their clinicians and review the primary trial publications or prescribing information for detailed data and individual suitability.
